ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, multi-centre, non-interventional post-marketing surveillance.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Retapamulin

Criteria

Inclusion Criteria:

• All subjects must satisfy the following criteria at study entry:

1. Subjects administered with ALTARGO(retapamulin) in the topical treatment of the following bacterial skin and skin structure infections (SSSI)

2. Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen

3. Subjects administered with ALTARGO(retapamulin) following the locally approved prescribing information

Exclusion Criteria:

• Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with retapamulin following the locally approved Prescribing Information.

1. Subjects with a known or suspected hypersensitivity to ALTARGO(retapamulin) or any component of the ointment

2. Infants under nine months of age